Related Experiment Video
Updated: Jan 9, 2026

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters
Published on: July 12, 2024
Air Pollution and Cardiac Biomarkers in Heart Failure: A Scoping Review
Gang Li1, Yan Hui Jia2, Yun Shang Cui3
1Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA;School of Medicine, Tsinghua University, Beijing 100084, China.
Ambient air pollution, particularly particulate matter, is linked to increased heart failure biomarkers like N-terminal pro-B-type natriuretic peptide and troponin. More research is needed to understand these environmental impacts on cardiovascular health.
Area of Science:
- Environmental Health
- Cardiology
- Biomarkers
Background:
- Ambient air pollution is a growing concern for cardiovascular health.
- Its specific impact on cardiac biomarkers in heart failure patients requires clarification.
Conclusions:
- Air pollution exposure is associated with adverse cardiac biomarker changes in heart failure.
- Integrating environmental risk assessment into heart failure care is crucial.
- Further research with enhanced exposure assessment and mechanistic evidence is recommended.
More Related Videos
07:35Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model
Published on: December 10, 2021
09:33Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India
Published on: December 23, 2022
Related Concept Videos
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure I: Introduction
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure VII: Nursing Interventions
Heart Failure III: Clinical Manifestations